Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Advanced Medical Solutions Group Debt-to-EBITDA?
Advanced Medical Solutions GroupCHIX:AMSL 93 Debt-to-EBITDA is 1.83 as of Dec. 2025, which is 438% above its 10-year median of 0.34. GuruFocus rates CHIX:AMSL with a GF Score™ of 93/100 and a GF Value™ of £3.72 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Advanced Medical Solutions Group ranks worse than 55.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Advanced Medical Solutions Group's Debt-to-EBITDA or its related term are showing as below:
CHIX:AMSl'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.28 Med: 0.34 Max: 2.93
Current: 1.85
During the past 13 years, the highest Debt-to-EBITDA Ratio of Advanced Medical Solutions Group was 2.93. The lowest was 0.28. And the median was 0.34.
CHIX:AMSl's Debt-to-EBITDA is ranked worse than 55.96% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs CHIX:AMSl: 1.85
Advanced Medical Solutions Group (CHIX:AMSl) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Advanced Medical Solutions Group Debt-to-EBITDA Related Terms
Advanced Medical Solutions Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Debt-to-EBITDA Chart
CHIX:AMSL vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Advanced Medical Solutions Group (CHIX:AMSL) has a Debt-to-EBITDA of 1.83 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Advanced Medical Solutions Group. This is 438% above median its historical median of 0.34. Over the past decade, Advanced Medical Solutions Group's Debt-to-EBITDA has ranged from 0.28 to 2.93. According to the industry distribution chart, Advanced Medical Solutions Group ranks #263 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 56%.
Is Advanced Medical Solutions Group's Debt-to-EBITDA too high?
Advanced Medical Solutions Group's current Debt-to-EBITDA of 1.83 is 438% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 2.93. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Advanced Medical Solutions Group's value of 1.83 is 15.5% above this industry median. Based on the distribution chart, Advanced Medical Solutions Group ranks #263 out of 470 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Advanced Medical Solutions Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #263 out of 470 companies for Debt-to-EBITDA. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.59. Advanced Medical Solutions Group's value of 1.83 is 15.5% above this benchmark. Historically, Advanced Medical Solutions Group's own Debt-to-EBITDA has ranged from 0.28 to 2.93 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 1.59, Advanced Medical Solutions Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Medical Solutions Group's current Debt-to-EBITDA of 1.83 is 15.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Advanced Medical Solutions Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Debt-to-EBITDA is 1.83, which is 438% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.72, compared to a current price of £2.80 — trading 24.9% below its estimated fair value. The current Debt-to-EBITDA is 1.83, which is 438% above median its 10-year median of 0.34 and 15.5% above the Medical Devices & Instruments industry median of 1.59. Advanced Medical Solutions Group's overall GF Score™ is 93/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Debt-to-EBITDA is 1.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.80 is trading 24.9% below its estimated GF Value™ of £3.72.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Debt-to-EBITDA: 1.83 (438% above median its 10-year median of 0.34)
GF Value™: £3.72 vs. price of £2.80 (24.9% below fair value)
Industry Position: 15.5% above the Medical Devices & Instruments median (#263 of 470)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
93GF Score
Get the complete analysis for CHIX:AMSL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
